Drug intelligence / Profile preview

BMS-986183

Development stage: Discontinued
Lead developer: Bristol Myers Squibb
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

BMS-986183 is an investigational antibody-drug conjugate (ADC) developed by Bristol Myers Squibb for the treatment of hepatocellular carcinoma and other neoplasms. Its mechanism of action involves targeting Glypican-3 (GPC3), a cell surface protein frequently overexpressed in liver cancers. The drug was designed to deliver a cytotoxic payload specifically to GPC3-expressing tumor cells via its antibody component. Clinical development reached up to phase 2 trials for advanced hepatocellular carcinoma but has since been discontinued[1][2][3][4].

Targets

GPC3 (Glypican-3)

Beyond the preview

Go deeper on BMS-986183.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BMS-986183.

Explore the full profile